A metabolic disorder, diabetes occurs because of inadequate insulin production by the pancreatic beta cells coupled with a poor response to insulin by muscle, fat, and liver cells (termed insulin resistance). Although insulin therapy and diabetes medications are adequate to regulate glucose homeostasis, the quality of life for some diabetes patients remains low as a result of life-endangering hypoglycemic episodes and multi-organ complications (e.g., eyes, vascular system, kidneys, and nervous system). T erefore, current translational ef orts in the regenerative medicine arena focus on cell replacement therapies for the replenishment of insulin-producing beta cells. Some of these strategies involve the generation of beta cells from pluripotent stem cells and endogenous endodermal derivatives such as hepatocytes and gastrointestinal, pancreatic ductal, acinar, or other endocrine cells (1) .
T e existence of a "pancreatic stem cell" remains elusive, but pancreatic plasticitythat is, transdif erentiation from one pancreatic cell type to another-such as evidence of insulin-producing beta-like cells within exocrine tissue (acinar and ductal cells) has gained considerable attention. Early experiments carried out by Bonner-Weir and Heimberg suggest some form of pancreatic plasticity and an intrinsic ability of the adult pancreas to regenerate (see Table 1 ). T ese studies demonstrate that beta cells can be restored in times of need, such as during injury and cellular stress. More recently, a wave of literature uncovering the potential of exocrine and endocrine cells to transdif erentiate and regenerate pancreatic beta cells, both in vitro and in vivo, has emerged. Furthermore, work by several groups has brought to light the phenomenon of beta cell dedif erentiation under physiological and pathophysiological states.
From a clinical point of view, these f ndings underscore the inherent plasticity of the pancreas and suggest the possibility of stimulating endogenous beta cell neogenesis or regeneration in vivo without the need for invasive methodologies. Here, we brief y summarize the literature and present a perspective on how plasticity associated with human pancreatic exocrine and endocrine cells, despite existing controversies, might potentially be harnessed for the regeneration of the beta cells in diabetic patients.
EXOCRINE CELL PLASTICITY
Nonphysiological stresses. T e concept of intrapancreatic cell-to-cell conversion, particularly under states of injury or cellular stress, is not new. Research on pancreatic duct ligation (PDL) and partial pancreatectomy (PPx) has been carried out since the 1600s, but evidence of acinar and ductal cell dif erentiation toward islet cell phenotypes in these pancreatic injury models began to emerge in the f rst decade of the 1900s (2) . More recently, cell lineage-tracing experiments demonstrated that, af er birth and af er PDL injury, carbonic anhydrase II (CAII)-expressing ductal epithelial cells in the pancreas give rise to new acinar tissue (clusters of exocrine pancreas cells that synthesize, store, and secrete digestive enzymes) and islets of Langerhans (which contains, alpha, beta, delta, PP, and epsilon cells) (3) . In addition, Heimberg and colleagues demonstrated that in response to PDL, cells in the ductal lining of the mouse exocrine pancreas can be converted into endocrine progenitors guided by the expression of neurogenin 3 (Ngn3), a key transcription factor for endocrine pancreas specif cation (4) . T ese Ngn3 + progenitor cells can subsequently contribute to beta cell neogenesis and proliferation, leading to the doubling of beta cell volume. Importantly, a selective knock out (KO) of Ngn3 in preexisting beta cells does not ablate this ef ect, suggesting that beta cell neogenesis occurs from non-beta cells (5) .
Lineage tracing of exocrine acinar-toendocrine cell transdif erentiation af er PDL in rodents was f rst reported by Pan et al. (6) . Af er PDL and elimination of pre-existing beta cells via treatment with streptozotocin (STZ, a chemical of microbial origin that is toxic to beta cells and used to create rodent diabetes models), the authors lineage-traced pancreas-specif c transcription factor 1a (Ptf1a)-expressing acinar cells and showed that these cells give rise to endocrine beta cells via Ck19 + /Hnf1β + /Sox9 + ductal and Ngn3 + endocrine pancreas progenitor intermediates in vivo. Acinar cell dedif erentiation into a progenitor-stage pancreatic cell (Pdx1 + Ecadherin + Beta-catenin + ) a f e r chemically (caerulein, an oligopeptide that causes pancreatitis)-induced pancreatic injury in vivo has also been reported (7) .
Collectively, these nonphysiological models demonstrate that exocrine cells in rodents, upon severe injury, prompt beta cell regeneration via transdif erentiation mechanisms (Fig. 1) . Human pancreatic exocrine cells (ductal cells) were successfully converted into beta-like cells recently, presenting a potential translational opportunity for human beta cell replacement (8, 9) .
Physiological stresses: Cytokines and nutrients. Multiple lines of evidence suggest that cytokine-and nutrient-induced physiological stresses also can promote exocrine cell-to-beta cell transdif erentiation (Table 1) high nutrient concentrations can also promote ductal cell-to-beta cell transdif erentiation (11) . T e ability of cytokines to promote exocrine cell-to-beta cell transdif erentiation as well as beta cell neogenesis has also been reported. In 1993, Gu and Sarvetnick f rst demonstrated that transgenic mice overexpressing interferon γ (IFN-γ) in pancreatic beta cells displayed proliferation and dif erentiation of pancreatic ductal cells into endocrine cells (12) . Af er a hiatus of two decades, another cytokine, tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), was shown to stimulate ductal cell proliferation and transient expression of Ngn3, ultimately giving rise to new pancreatic beta cells (13) . More recently, Baeyens et al. demonstrated that transient epidermal growth factor (EGF) and ciliary neurotrophic factor (CNTF) treatment stimulates Ngn3 expression in acinar cells, which subsequently transdif erentiated into beta cells and restored euglycemia in diabetic mice (14) .
Taken together, these experiments in model organisms highlight the plastic nature of the pancreas and suggest that it favors beta cell regeneration in states of stress. Notably, the fact that transient exposure to cytokines promotes acinar cellto-beta cell transdif erentiation in mice (14) means that it might be possible to use such an intervention to regenerate human pancreatic beta cells in vivo (Fig. 1) . T is is of high clinical and translational relevance because diabetic patients are typically exposed to inf ammatory cytokines and prolonged low-grade inf ammation. T is means that the appropriate use of the correct cytokines may eventually serve to restore pancreatic beta cell function (15) .
PLASTICITY: ADULT CONTROVERSIES
Although the evidence highlighted above suggests the presence of beta cell progenitors within adult exocrine cells, there are also numerous opposing studies indicating that this is not the mechanism by which adult beta cells regenerate (at least in rodents). In pancreatic injury models such as PPx (16) and diphtheria toxin-based beta cell depletion (17) , it was found that new beta cells arise predominantly from proliferation of preexisting beta cells during adult life. Subsequent studies proposed that pancreatic ductal cells give rise to beta cells during pancreatic embryogenesis but not af er birth following experimentally induced injury models such as PDL (18) and alloxan-induced beta cell ablation (19) . Using lineage-tracing studies in various models of beta cell loss, Xiao et al. did not f nd evidence of beta cell neogenesis in adult mice despite an up-regulation of Ngn3 in proliferating duct cells and in preexisting beta cells (20) . Rankin et al. performed PDL and comprehensive whole pancreas beta cell quantif cation to conclude that no progenitors contribute to beta cell mass regeneration. Accordingly, PDL stimulates excessive pancreatic injury, thereby af ecting the way by which beta cell content can be accurately measured (21) .
Despite
ENDOCRINE CELL PLASTICITY
Nonphysiological stresses: Chemically induced beta cell death and PDL. Given the abundance of pancreatic exocrine versus endocrine tissue, it is not surprising that there has been a huge focus on exocrine cell transdif erentiation for regenerative medicine purposes. Many groups have performed excellent work to demonstrate that pancreatic alpha cells can actually transdif erentiate into beta cells-a degree of pancreatic plasticity that had been neglected ( Fig. 1 and Table 1 ). Using nonphysiological models, breakthrough work b y T o r e l et al. demonstrated that diphtheria toxin-induced beta cell depletion can promote alpha cell-to-beta cell transdifferentiation (23) . Subsequently, Chung et al. combined PDL with high-dose alloxan (a chemical that destroys beta cells) in mice to demonstrate that, in adult animals, new beta cells are primarily derived from alpha cells (24) . More recently, the same group showed that transdif erentiation of alphato-beta-to-delta cells could be observed in mice (in vivo) following caerulein treatment and in human type 1 diabetic pancreatic sections (ex vivo) (25) . On the basis of their f ndings, the authors proposed that autoim- CREDIT: V. ALTOUNIAN/SCIENCE TRANSLATIONAL MEDICINE munity plays a role in islet-cell interconversion, which has enormous implications for the treatment of human type 1 diabetes (25) .
Physiological stress. Physiological stresses such as insulin resistance, chronic hyperglycemia, multiparity, aging, and oxidative stress also have been implicated in epigenetic actions that alter islet cell mass and interconversions (26) . T e comparison of insulin-resistant versus insulin-sensitive human pancreatic samples by Mezza et al. suggests that insulin resistance is linked to alpha (and ductal) cell-to-beta cell transdif erentiation in human type 2 diabetes patients (27) . In addition, beta cell plasticity in states of physiological stress has also been reported. In 1999, Jonas et al. demonstrated that PPx-induced hyperglycemia is marked by beta cell dysfunction and a loss of mature beta cell gene expression (28) . More recently, Talchai et al. reinvigorated the concept of beta cell plasticity by demonstrating that physiological stresses such as chronic hyperglycemia, multiparity, and aging induce beta cell dysfunction and dedif erentiation (29) . T e dedif erentiated beta cells reexpress Ngn3, and some of the cells revert to alpha cells. T ese results were subsequently conf rmed in other mouse models of metabolic stress (29) . Remarkably, dedif erentiated Ngn3 
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+ beta cells af er insulin therapy, raising hopes that the loss of beta cell function in humans might be reversible (30) . Another recent study indicates that, in islets from human type 2 diabetes patients, oxidative stress-associated beta cell dysfunction induces cytoplasmic translocation and inactivation of MAFA, NKX6.1, and PDX1, all of which are mature beta cell transcription factors (31) . Collectively, these studies indicate that beta cell "dysfunction" may be a ref ection of stress-induced beta cell dedif erentiation.
From a translational medicine standpoint, the ability to (i) halt the dedif erentiation process of beta cells, (ii) redif erentiate these stress-derived beta cell "progenitors, " and (iii) facilitate alpha cell-to-beta cell conversion would allow potential repopulation of the functional beta cell pool in diabetic patients.
NGN3, A CENTRAL PLAYER
A common theme within the f eld of pancreatic plasticity-mechanisms of trans-or dedif erentiation-is focused on the reemergence of Ngn3 expression in terminally dif erentiated adult cells. Ngn3 is a transcription factor and master regulator that determines pancreatic endocrine cell (33) , but the expression pattern of Ngn3 in the mouse is distinctly dif erent from that in humans (34) . Importantly, Ngn3 is also purportedly expressed in the adult pancreas, whereby it is essential for the expression of beta cell genes that encode NeuroD1, Pax4, MafA (pancreatic developmental transcription factors), and insulin (35) . Further investigations are warranted to determine the signif cance of reemergence of Ngn3 expression in these transdif erentiation observations. Speculatively, should the Ngn3 expression result in increased alpha cell formation, as suggested by Talchai et al. (29) , the increased glucagon and glucagonlike peptide 1 (GLP-1) secreted by the new alpha cells might promote beta cell formation (36) . Furthermore, it may be worthwhile to ectopically stimulate Ngn3 expression should it eventually be determined to be critical for the transdif erentiation of human exocrine or alpha cells to beta cells.
CHALLENGES AND PROSPECTS
Ample evidence indicates that the pancreas possesses the plasticity that allows it to regenerate under various states of stress. However, several challenges remain. First, misappropriated plasticity might be a threat, as inf ammatory stress can lead to pancreatitis-a major risk factor for developing pancreatic adenocarcinoma (37) . It is important to recognize that embryonic pathways, such as NOTCH signaling, that play a role in acinar regeneration during pancreatic development have also been linked to neoplastic transformation (37) . T e second challenge relates to understanding and controlling how stress mechanisms can be used to induce the desired cell type. For example, during states of metabolic stress, Talchai et al. demonstrated that dedif erentiated beta cells are able to redif erentiate, albeit adopting an alpha cell fate instead (29) . Furthermore, the f nding that Ngn3 + progenitors observed in diabetic mice can redif erentiate into insulin + cells upon insulin therapy is critical, because it suggests that the presence of cellular stress might also hinder the redif erentiation of these progenitors into mature beta cells (30) . In conclusion, stressinduced pancreatic plasticity is a controversial area of research on a process that still is not fully understood. Nevertheless, there is great promise that unraveling its intricate mechanisms will allow us to translate these f ndings into therapies that contribute to pancreatic regenerative medicine.
